The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.
Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to $335 million.
The acquisition has been reported by Israeli ophthalmology investment firm BioLight Industries (TASE: BOLT), which notified the Tel Aviv Insieme Exchange (TASE) that it will receive an immediate payment of NIS 9 million and additional milestone payments of up to $10.5 million for its 4% stake per mezzo di the company.
From these numbers it is possible to calculate that Alcon is making an immediate payment of $60 million for Belkin Vision and milestone payments that would bring the total of the acquisition up to $335 million. BioLight, which had booked the value of its per mezzo di Belkin Vision as just NIS 3.6 million, saw its share price rise 32.6% today.
Belkin Vision has developed a laser treatment for glaucoma. Last December, the Yavne-based company received FDA approval to market its laser device per mezzo di the US. The company was founded per mezzo di 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin to develop a non-contact laser treatment that is more effective and accessible per mezzo di the treatment of glaucoma.
Durante February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company is led by CEO Daria Lemann-Blumenthal, while Prof. Belkin serves as medical director.
Published by Globes, Israel business news – en.globes.co.il – acceso May 5, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
Dollars credit: Colin Watts, Unsplashed
